MARKSANS — Marksans Pharma Balance Sheet
0.000.00%
- IN₹84.00bn
- IN₹79.58bn
- IN₹21.77bn
- 75
- 15
- 90
- 67
Annual balance sheet for Marksans Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 931 | 2,094 | 3,467 | 7,151 | 7,075 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,434 | 2,714 | 3,978 | 4,195 | 4,581 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,936 | 9,023 | 12,012 | 16,753 | 18,625 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,300 | 2,540 | 3,423 | 3,869 | 6,811 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 9,027 | 12,283 | 16,401 | 21,904 | 26,810 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,288 | 2,984 | 3,562 | 3,410 | 3,898 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2,667 | 3,418 | 4,378 | 4,452 | 6,159 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 6,360 | 8,865 | 12,023 | 17,452 | 20,651 |
Total Liabilities & Shareholders' Equity | 9,027 | 12,283 | 16,401 | 21,904 | 26,810 |
Total Common Shares Outstanding |